Brenzys biosimilar etanercept regulatory update

Samsung Bioepis Co. Ltd. and Merck said Canada approved Brenzys etanercept, a biosimilar of autoimmune drug Enbrel etanercept, to treat rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Merck will commercialize the biosimilar in Canada. The pharma said the market price of the biosimilar will be equivalent to a 15-25% discount to Enbrel, depending on the province. The product is approved in Korea and Australia as Brenzys and in the EU as Benepali. ...